 | This article needs additional citations for verification .(September 2015) (Learn how and when to remove this template message) |
International Medical Press is a small medical publishing company, based in London. It also has offices in Atlanta and the Asia-Pacific region. International Medical Press is currently part of The Nucleus Group. The company was founded in 1996.
International Medical Press publishes two peer-reviewed medical journals in antiviral research:
The contents of both journals are freely available online as PDFs after 12 months (and at publication for individuals in developing countries), via the journal websites.
International Medical Press also runs conferences and publishes books, mainly in the virology area, including the Human Virus Guides series. It formerly published the monthly newsletter International Antiviral News ( ISSN 0965-2310).
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 | This article about a publishing company in the United Kingdom is a stub. You can help Wikipedia by expanding it. |
Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit their development.
Ribavirin, also known as tribavirin, is an antiviral medication used to treat RSV infection, hepatitis C and some viral hemorrhagic fevers. For hepatitis C, it is used in combination with other medications such as simeprevir, sofosbuvir, peginterferon alfa-2b or peginterferon alfa-2a. Among the viral hemorrhagic fevers it is used for Lassa fever, Crimean–Congo hemorrhagic fever, and Hantavirus infection but should not be used for Ebola or Marburg infections. Ribavirin is taken by mouth or inhaled.
Butylated hydroxytoluene (BHT), also known as dibutylhydroxytoluene, is a lipophilic organic compound, chemically a derivative of phenol, that is useful for its antioxidant properties. BHT is widely used to prevent free radical-mediated oxidation in fluids and other materials, and the regulations overseen by the U.S. F.D.A.—which considers BHT to be "generally recognized as safe"—allow small amounts to be added to foods. Despite this, and the earlier determination by the National Cancer Institute that BHT was noncarcinogenic in an animal model, societal concerns over its broad use have been expressed. BHT has also been postulated as an antiviral drug, but as of March 2020, use of BHT as a drug is not supported by the scientific literature and it has not been approved by any drug regulatory agency for use as an antiviral.
Aciclovir (ACV), also known as acyclovir, is an antiviral medication. It is primarily used for the treatment of herpes simplex virus infections, chickenpox, and shingles. Other uses include prevention of cytomegalovirus infections following transplant and severe complications of Epstein-Barr virus infection. It can be taken by mouth, applied as a cream, or injected.
Mark Arnold Wainberg, was a Canadian HIV/AIDS researcher and HIV/AIDS activist. He was the Director of the McGill University AIDS Centre at the Montreal Jewish General Hospital and Professor of Medicine and of Microbiology at McGill University. His laboratory primarily studies HIV reverse transcriptase, the molecular basis for drug resistance, and gene therapy. He received a B.Sc. from McGill University in 1966, a Ph.D. from Columbia University in 1972, and did his post-doctoral research at Hadassah Medical School of the Hebrew University.
Antiviral Therapy is a peer-reviewed medical journal published by International Medical Press. It publishes primary papers and reviews on all aspects of the clinical development of antiviral drugs, including clinical trial results, drug resistance, viral diagnostics, drug safety, pharmacoepidemiology, and vaccines. Antiviral Therapy is an official publication of the International Society for Antiviral Research.
Douglas D. Richman is an American infectious diseases physician and medical virologist. Richman's work has focused on the HIV/AIDS pandemic, since its appearance in the early 1980s. His major contributions have been in the areas of treatment, drug resistance, and pathogenicity.
Umifenovir, sold under the brand name Arbidol, is an antiviral medication for the treatment of influenza infection used in Russia and China. The drug is manufactured by Pharmstandard. Although some Russian studies have shown it to be effective, it is not approved by the US FDA for the treatment or prevention of influenza.
Dove Medical Press is an academic publisher of open access peer-reviewed scientific and medical journals, with offices in Manchester, London, Princeton, New Jersey, and Auckland. In September 2017, Dove Medical Press was acquired by the Taylor and Francis Group.
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bimonthly by International Medical Press. It was established in January 1990 and published by Blackwell Publishing until 1997. The editor-in-chief is Hugh J. Field. The journal covers research on all aspects of the preclinical development of antiviral drugs, including their chemical synthesis, biochemistry, pharmacology, mode of action, and virology, as well as studies in animal models. The journal is an official publication of the International Society for Antiviral Research.
Antiviral Research is a monthly peer-reviewed medical journal published by Elsevier covering research on all aspects of the development of drugs, vaccines and immunotherapies against viruses of animals and plants. The journal was established in 1981 and is an official publication of the International Society for Antiviral Research. The editor-in-chief is Mike Bray.
Pulsus Group is a publisher of scientific, technical, and medical literature. It was formed in 1984, primarily to publish peer-reviewed medical journals. As of 2016, Pulsus published 49 hybrid and full open-access journals, 15 of which had been adopted as the official publications of the related medical societies. Pulsus Group also conducts conferences in association with scientific societies.
Karger Publishers is an academic publisher of scientific and medical journals and books. The current CEO is Gabriella Karger.
IOS Press is a publishing house headquartered in Amsterdam, specialising in the publication of journals and books related to fields of scientific, technical, and medical research. Established in 1987, IOS Press publishes around 100 international journals and releases about 75 book titles annually, covering fields such as computer science, mathematics, the natural sciences, and topics within medicine.
EDP Sciences is an STM publisher that specialises scientific information for specialist and more general audiences. EDP produces and publishes international journals, books, conferences, and websites with predominantly scientific and technical content. The company is a joint venture of four French learned societies in science, mathematics, and medicine.
The Journal of Antibiotics is a peer-reviewed medical journal published by the Nature Publishing Group for the Japan Antibiotics Research Association.
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.
Thomas Charles Merigan is an American virologist and the George E. and Lucy Becker Professor of Medicine, Emeritus at the Stanford University School of Medicine. Merigan's research first focused on viral pathogenesis, basic and clinical studies of interferon, and then developing the first systemic antiviral drugs including those effectively treatIng HIV/AIDS. He is also credited with helping to develop the use of interferons as antiviral and antitumor therapies. Merigan joined the Stanford faculty in 1963 and assumed full emeritus status in 2007. In 2004 he was also identified as one of the 250 most cited investigators in clinical medicine over the last 20 years by the Institute for Scientific Information. He had over 90 postdoctoral fellows, students and visiting scientists with whom he published 576 papers, 24 books and published symposia, and held 11 US patents. His students have become leaders in the fields of infectious diseases and microbiology. He was a board member of 28 journals and a member of 23 learned societies. He told his life story in a book entitled Pioneering Viral Therapy,a Life in Academic Medicine, published by Amazon/Kindle/CreateSpace in 2017.
Remdesivir, sold under the brand name Veklury, is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. Remdesivir is being tested as a treatment for COVID‑19, and has been authorized for emergency use in the US, India, Singapore, and approved for use in Japan, the European Union, and Australia for people with severe symptoms. It also received approval in the UK in May 2020; however, it was going to be rationed due to limited supply. It may shorten the time it takes to recover from the infection.
Drug repositioning is the re-purposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.
